184 related articles for article (PubMed ID: 16623609)
1. Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches.
Gershovich OE; Billups SJ; Delate T; Hoffman CK; Carroll N
J Manag Care Pharm; 2006 Apr; 12(3):246-53. PubMed ID: 16623609
[TBL] [Abstract][Full Text] [Related]
2. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine.
Loder E; Brandes JL; Silberstein S; Skobieranda F; Bohidar N; Wang L; Boyle D; Kolodny A; Guerra F; Santanello N; Johnson-Pratt L;
Headache; 2001 Sep; 41(8):745-53. PubMed ID: 11576197
[TBL] [Abstract][Full Text] [Related]
3. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
McCormack PL; Foster RH
Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine.
Zhang L; Hay JW
CNS Drugs; 2005; 19(7):635-42. PubMed ID: 15984898
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders.
Seeburger JL; Taylor FR; Friedman D; Newman L; Ge Y; Zhang Y; Hustad CM; Lasorda J; Fan X; Hewitt D; Ho T; Connor KM
Cephalalgia; 2011 May; 31(7):786-96. PubMed ID: 21078681
[TBL] [Abstract][Full Text] [Related]
6. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine.
Pascual J; Bussone G; Hernandez JF; Allen C; Vrijens F; Patel K;
Eur Neurol; 2001; 45(4):275-83. PubMed ID: 11385269
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of rizatriptan in the treatment of migraine.
Thompson M; Gawel M; Desjardins B; Ferko N; Grima D
Pharmacoeconomics; 2005; 23(8):837-50. PubMed ID: 16097844
[TBL] [Abstract][Full Text] [Related]
8. Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study.
Solomon S; Frishberg B; Hu XH; Markson L; Berger M
Clin Ther; 2001 Jun; 23(6):886-900. PubMed ID: 11440288
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain.
Pascual J; Fité B; López-Gil A
Headache; 2002 Feb; 42(2):93-8. PubMed ID: 12005301
[TBL] [Abstract][Full Text] [Related]
10. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray.
Hoffman L; Mayzell G; Pedan A; Farrell M; Gilbert T
J Manag Care Pharm; 2003; 9(4):335-45. PubMed ID: 14613452
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours.
Adelman JU; Belsey J
J Manag Care Pharm; 2003; 9(1):45-52. PubMed ID: 14613361
[TBL] [Abstract][Full Text] [Related]
13. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
Mitchell MP; Schaecher K; Cannon HE; Speckman M
J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
[TBL] [Abstract][Full Text] [Related]
14. Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis.
Seeburger JL; Cady RK; Winner P; MacGregor A; Valade D; Ge Y; Zhang Y; Hustad CM; Strickler N; Schaefer E; Connor KM; Ho TW
Headache; 2012 Jan; 52(1):57-67. PubMed ID: 22078129
[TBL] [Abstract][Full Text] [Related]
15. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan.
Díez FI; Straube A; Zanchin G
J Neurol; 2007 Feb; 254(2):242-9. PubMed ID: 17334957
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine.
Williams P; Reeder CE
Clin Ther; 2003 Nov; 25(11):2903-19. PubMed ID: 14693315
[TBL] [Abstract][Full Text] [Related]
17. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
[TBL] [Abstract][Full Text] [Related]
18. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group.
Visser WH; Terwindt GM; Reines SA; Jiang K; Lines CR; Ferrari MD
Arch Neurol; 1996 Nov; 53(11):1132-7. PubMed ID: 8912486
[TBL] [Abstract][Full Text] [Related]
19. Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat.
Mullins CD; Weis KA; Perfetto EM; Subedi PR; Healey PJ
J Manag Care Pharm; 2005 Jun; 11(5):394-402. PubMed ID: 15934798
[TBL] [Abstract][Full Text] [Related]
20. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.
Lofland JH; Johnson NE; Batenhorst AS; Nash DB
Arch Intern Med; 1999 Apr; 159(8):857-63. PubMed ID: 10219932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
